New SGLT2 Inhibitors (Kidney & Heart) treatments in trials

Empagliflozin, Dapagliflozin — glycaemic control, heart failure & chronic kidney disease. Track the treatments still in clinical testing and see which are closest to an FDA decision.

72Closest to approval (Phase 3)

68Mid-stage (Phase 2)

59Early stage (Phase 1)

868Total recruiting

In one line

868 sglt2 inhibitors (kidney & heart) trials are recruiting right now, 72 of them in Phase 3 — the stage immediately before an FDA decision.

Recruiting now

Twelve of the currently recruiting studies. Open one for a plain-English summary of who it is for and what it involves.

NCT06704672NARecruitingClinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes MellitusSponsorHoffmann-La RocheEnrolling270Summary NCT07375069RecruitingCharacterization of Cardiovascular Risk Profile and Therapeutic Management in Patients With Type 2 Diabetes Mellitus in ItalySponsorFederico II UniversityEnrolling3,000Summary NCT07351058Phase 3RecruitingA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesSponsorHoffmann-La RocheEnrolling1,600Summary NCT06046833NARecruitingContinuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 DiabetesSponsorSamita GargEnrolling50Summary NCT04932928NARecruitingPatient-Driven Lifestyle Modification Using FreeStyle Libre in Type 2 Diabetes PatientsSponsorSeoul National University HospitalEnrolling126Summary NCT06319716NARecruitingLINK-IT: Leveraging vIdeos and commuNity Health worKers to Improve Diabetes OuTcomesSponsorNYU Langone HealthEnrolling540Summary NCT05692778RecruitingOptimized Care of People With Diabetes and Foot Complication in Primary CareSponsorSahlgrenska University HospitalEnrolling140Summary NCT07392190Phase 3RecruitingA Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinSponsorEli Lilly and CompanyEnrolling900Summary NCT07260110RecruitingA Longitudinal, Observational Study Comparing Real-World Experiences of Teplizumab-Treated and Untreated Participants With Stage 2 Type 1 Diabetes in the United StatesSponsorSanofiEnrolling550Summary NCT07554443NARecruitingWearable Sensory Prosthesis to Improve Coordination, Walking, and Physical ActivitySponsorRxFunction Inc.Enrolling18Summary NCT05687968NARecruitingInnovative Approaches in Diabetes CareSponsorTaipei Medical UniversityEnrolling39Summary NCT06887049NARecruitingAchieving Routine Intervention and Screening for Emotional HealthSponsorUniversity of ChicagoEnrolling1,250Summary

View all 868 on ClinicalTrials.gov

Already approved for this area

SGLT2 Inhibitors

Jardiance, Farxiga, Invokana, Steglatro — approved products with their NDC records and billing codes.

Open the class

Every NDC in this class

The FDA registry filtered to sglt2 inhibitors, with packaging and 11-digit billing conversions.

Search the directory

Loading the trial explorer…